Create Account | Forget Password?               
Home Asthma Cancer Cardiology Diabetes Neurology Nutrition Pediatrics OB / GYN General
Health Center
Ads & Resources
Comprehensive Health Directory
Manage Patient Records
 
Home » Asthma
 Asthma Videos  « Go Back

Dynavax Receives Milestone from AstraZeneca : Novel Asthma/COPD Drug Candidate Nominated for Clinical Development

Posted By: Anonymous | Posted On: Sep 21,2008 18:30 pm | View: 21
Dynavax Technologies, Inc. (NASDAQ:DVAX) today announced receipt of a $4.5 million milestone payment from its partner AstraZeneca AB for the nomination of candidate drug AZD1419 for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of this potential $136 million development and commercialization collaboration, AstraZeneca and Dynavax have initiated Investigational New Drug (IND) enabling studies with AZD1419 and plan to begin phase 1 clinical development in 2009. Read More: http://www.prweb.com/releases/dynavax_technologies/clinical_development/prweb1368074.htm



 
Other Health Sources
About Us |  Contact Us |  Asthma |  Cancer |  Cardiology |  Diabetes |  Neurology |  Diet & Nutrition |  Pediatrics |  OB/GYN |  General
Copyright © 2008-2012, DoctorsOutlook.com, All Rights Reserved.
Disclaimer: Issuers of the submissions/postings are solely responsible for the content of their submissions. Doctorsoutlook.com can't be held liable for the contents of these submissions. In case any submission damages your benefits or violate your rights in any way, please contact us and we'll remove it immediately.